Last updated on December 2018

Home Therapy With VPRIV in Gaucher's Disease

Brief description of study

The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Gaucher's Disease receiving their enzyme replacement therapy with VPRIV (Velaglucerase alfa)at their home setting compared to receiving the infusions at the clinic or at doctor's practice.

Clinical Study Identifier: NCT01356537

Contact Investigators or Research Sites near you

Start Over

Yildiz Yildiz, MD

Landeskrankenhaus Bregenz
Bregenz, Austria

Florian B. Lagler, MD

Paracelsus Medizinische Privatuniversit t Salzburg
Salzburg, Austria

Vassiliki Konstantopoulou, MD

AKH, Allgemeines Krankenhaus der Stadt Wien
Wien, Austria

Thomas Stulnig, MD

Medical University of Vienna
Wien, Austria

Thomas Stulnig, MD

Medizinische Universit t Wien
Wien, Austria

Shire Contact

Endocrinology in the center
Erlangen, Germany

Shire Contact

Facharzt f r Chirurgie und Orthop die
Hamburg, Germany

Shire Contact

Gastroenterological FOCUS PRACTICE Dr. med. Hans Werner Karch
Kirn, Germany

Eugen Mengel, MD

Universit tsklinikum Mainz
Mainz, Germany

Arndt Rolfs, MD

Albrecht-Kossel-Institut f r Neuroregeneration (AKos)
Rostock, Germany

Peter Clemens, MD

Helios Klinikum Schwerin
Schwerin, Germany

Prof. Michael Leichsenring, MD

Universit tsklinikum Ulm
Ulm, Germany

Shire Contact

Praxis f r Innere Medizin
Wallgau, Germany

Achim Rothe, MD

Gemeinschaftspraxis f r H matologie und Onkologie
Köln, Germany

Shire Contact

Group Practice, Drs Klaus Michels and Michels Alexander
Mühlhausen, Germany

Claudia Regenbogen, MD

Klinikum rechts der Isar
München, Germany

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.